Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1387-1394

  Liu, Xiaozhi ^a,b   Li, Gang ^a   Su, Zhiguo ^a,b   Jiang, Zhongmin ^a   Chen, Lei ^a,b   Wang, Junfei ^a,b   Yu, Shizhu ^c,d   Liu, Zhenlin ^a,b  

^a TIANJIN FIFTH CENTRAL HOSPITAL   (China)

^b Tianjin Binhai Neurological Institute   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Epidermal growth factor receptor; Folic acid; Glioma; MicroRNA 7; Poly(amido amine)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; MICRORNA; MICRORNA 7; POLYAMIDOAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EXPRESSION VECTOR; GENE SILENCING; GENETIC TRANSFECTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR CELLS AND CELL LINES; U251 CELL;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; DENDRIMERS; DRUG CARRIERS; GENE SILENCING; GLIOMA; HUMANS; LIPOSOMES; MICE; MICRORNAS; POLYAMINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84874728069     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2283     Document Type: Article

References (22)

1. Nakamura M, Shimada K, Nakase H, et al: Clinicopathological diagnosis of gliomas by genotype analysis. Brain Nerve 61: 773-780, 2009 (In Japanese). 2. Mladkova N and Chakravarti A: Molecular profiling in glioblas¬toma: prelude to personalized treatment. Curr Oncol Rep 11: 53-61, 2009.
2. Huang H, Mahler-Araujo BM, Sankila A, et al: APC mutations in sporadic medulloblastomas. Am J Pathol 156: 433-437, 2000.
3. Gilbertson RJ: Medulloblastoma: signalling a change in treatment. Lancet Oncol 5: 209-218, 2004.
4. Misaki K, Marukawa K, Hayashi Y, et al: Correlation of gamma-catenin expression with good prognosis in medulloblastomas. J Neurosurg 102: 197-206, 2005.
5. Ellison DW, Onilude OE, Lindsey JC, et al: beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23: 7951-7957, 2005.
6. Oikonomou E, Barreto DC, Soares B, et al: Beta-catenin mutations in craniopharyngiomas and pituitary adenomas. J Neurooncol 73: 205-209, 2005.
7. Sekine S, Shibata T and Kokubu A: Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161: 1997-2001, 2002.
8. Gonzalez S, Pisano DG and Serrano M: Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle 7: 2601-2608, 2008.
9. Croce CM: Causes and consequences of microRNA dysregula¬tion in cancer. Nat Rev Genet 10: 704-714, 2009.
10. Novakova J, Slaby O, Vyzula R, et al: MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun 386: 1-5, 2009.
11. Si ML, Zhu S, Wu H, et al: miR-21-mediated tumor growth. Oncogene 26: 2799-2803, 2007.
12. Tong AW and Nemunaitis J: Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 15: 341-355, 2008.
13. Kefas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572, 2008.
14. Yang H: Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res 27: 1759-1771, 2010.
15. Tomalia DA: A new class of polymers: starburst-denfritic macro¬molecules. Polym J 17: 117-132, 1985.
16. Malik N, Wiwattanapatapee R, Klopsch R, et al: Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled poly¬amidoamine dendrimers in vivo. J Control Release 65: 133-148, 2000.
17. Huang S, Fu L, Zhang X, et al: Syntheses of polyamidoamine dendrimers starting from a hexadimensional core and applica¬tion in gene transfer. Science in China Series B: Chemistry 46: 271-279, 2003.
18. Tang MX, Redemann CT and Szoka FC Jr.: In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 7: 703-714, 1996.
19. Luo D, Haverstick K, Belcheva N, et al: Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible, high-efficiency DNA delivery. Macromolecules 35: 3456-3462, 2002.
20. Belda-Iniesta C, de Castro Carpeño J, Sereno M, et al: Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. Clin Transl Oncol 10: 73-77, 2008.
21. Loew S, Schmidt U, Unterberg A, et al: The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 9: 703-715, 2009.
22. Zi X, Guo Y, Simoneau AR, et al: Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65: 9762 9770, 2005.